ZS Pharma, Inc. clinical trials
Acquired by AstraZeneca, Dec 17, 2015 · source ↗
The registry lists 8 studies whose lead sponsor is ZS Pharma, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 7, 2018.
- 8studies on the registry
- 0open to participants now
Before and after it joined AstraZeneca
- First submitted before ZS Pharma, Inc. became part of AstraZeneca
- 8
- First submitted after ZS Pharma, Inc. became part of AstraZeneca
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs ZS Pharma, Inc.’s studies test, most studies first; none is open now — 2 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- sodium zirconium cyclosilicate3 in phase 30 open · 3
- 0 open · 1
All 8 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 11
- 12
- 13
- 314
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- ZS Pharma, Inc.8 studies
Something wrong with this grouping? Tell us on the AstraZeneca page.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. All AstraZeneca studies →
- Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.CompletedNCT02088073Phase 3
Sponsor listed in the registry: ZS Pharma, Inc. · First submitted before ZS Pharma, Inc. became part of AstraZeneca
- Safety & Efficacy of Zirconium Silicate in Mild to Moderate HyperkalemiaCompletedNCT01737697Phase 3
Sponsor listed in the registry: ZS Pharma, Inc. · First submitted before ZS Pharma, Inc. became part of AstraZeneca
- Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.CompletedNCT02107092Phase 3
Sponsor listed in the registry: ZS Pharma, Inc. · First submitted before ZS Pharma, Inc. became part of AstraZeneca
- Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild HyperkalemiaCompletedNCT01493024Phase 2
Sponsor listed in the registry: ZS Pharma, Inc. · First submitted before ZS Pharma, Inc. became part of AstraZeneca
- Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 MonthsCompletedNCT02163499Phase 3
Sponsor listed in the registry: ZS Pharma, Inc. · First submitted before ZS Pharma, Inc. became part of AstraZeneca
- POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational StudyCompletedNCT02609841
Sponsor listed in the registry: ZS Pharma, Inc. · First submitted before ZS Pharma, Inc. became part of AstraZeneca
- REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational StudyCompletedNCT02607085
Sponsor listed in the registry: ZS Pharma, Inc. · First submitted before ZS Pharma, Inc. became part of AstraZeneca
- Safety and Efficacy of Sodium Polystyrene Sulfonate in HyperkalemiaTerminatedNCT01866709Phase 4
Sponsor listed in the registry: ZS Pharma, Inc. · First submitted before ZS Pharma, Inc. became part of AstraZeneca